-
Expanded conventional first trimester screening.
Carmichael JB, Liu HP, Janik D, Hallahan TW, Nicolaides KH, Krantz DA.
Prenat Diagn 2017;37:802-807. pdf -
Maternal serum anti-Mallerian hormone at 11-13 weeks' gestation in the prediction of preeclampsia.
Birdir C, Fryze J, Vasiliadis H, Nicolaides KH, Poon LC.
J Matern Fetal Neonatal Med 2015;28:865-8. pdf -
Maternal and foetal angiogenic imbalance in congenital heart defects.
Llurba E, Sánchez O, Ferrer Q, Nicolaides KH, Ruíz A, Domínguez C, Sánchez-de-Toledo J, García-García B, Soro G, Arévalo S, Goya M, Suy A, Pérez-Hoyos S, Alijotas-Reig J, Carreras E, Cabero L.
Eur Heart J 2014;35:701-7. -
First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing.
Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2014;35:118-26. pdf -
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014;35:185-92. pdf -
First-trimester screening for neural tube defects using alpha-fetoprotein.
Bredaki FE, Poon LC, Birdir C, Escalante D, Nicolaides KH.
Fetal Diagn Ther 2012;31:109-14. -
Screening for fetal aneuploidies at 11 to 13 weeks.
Nicolaides KH.
Prenat Diagn 2011;31:7-15. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
Maternal serum alpha-fetoprotein in normal pregnancy at 11-13 weeks' gestation.
Bredaki FE, Wright D, Akolekar R, Cruz G, Nicolaides KH.
Fetal Diagn Ther 2011;30:274-9. -
First-Trimester Screening for Trisomy 21 Using Alpha-Fetoprotein.
Bredaki FE, Wright D, Matos P, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2011;30:215-8. -
Maternal serum a-fetoprotein at 11-13 weeks' gestation in spontaneous early preterm delivery.
Beta J, Bredaki FE, Calvo JR, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2011;30:88-93. -
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia.
Foidart JM, Munaut C, Chantraine F, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;35:680-7. -
Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia.
Akolekar R, Cruz JJ, Foidart JM, Munaut C, Nicolaides KH.
Prenat Diagn 2010;30:191-7. -
Physiological distribution of placental growth factor and soluble Flt-1 in early pregnancy.
Makrydimas G, Sotiriadis A, Savvidou MD, Spencer K, Nicolaides KH.
Prenat Diagn 2008;28:175-9. -
First trimester maternal serum AFP and total hCG in aneuploidies other than trisomy 21.
Spencer K, Heath V, Flack N, Ong C, Nicolaides KH.
Prenat Diagn 2000;20:635-9. -
Maternal serum alpha-fetoprotein in fetal neural tube and abdominal wall defects at 10-14 weeks of gestation.
Sebire NJ, Spencer K, Noble PL, Hughes K, Nicolaides KH.
BJOG 1997;104:849-51. -
Fetal hepatic alpha-fetoprotein mRNA expression in fetuses with trisomy 21 and 18 at 12-15 weeks gestation.
Brizot ML, Mckie AT, von-Kaisenberg CS, Farzaneh F, Nicolaides KH.
Early Hum Dev 1996;44:155-9.